HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Mardente, S ^a   Mari, E ^a   Massimi, I ^a   Fico, F ^a   Faggioni, A ^a   Pulcinelli, F ^a   Antonaci, A ^a   Zicari, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTAGOMIR; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; MICRORNA 221; MICRORNA 222; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; HMGB1 PROTEIN, HUMAN; MICRORNA; MIRN221 MICRORNA, HUMAN; MIRN222 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; INFLAMMATION; INFLAMMATORY CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UPREGULATION; APOPTOSIS; CELL PROLIFERATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR;

APOPTOSIS; CELL PROLIFERATION; HMGB1 PROTEIN; HUMANS; MICRORNAS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84935876988     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/512027     Document Type: Article

References (30)

1. M. Garofalo, C. Quintavalle, G. Romano, C. M. Croce, and G. Condorelli, "MiR221/222 in cancer: their role in tumor progression and response to therapy," Current Molecular Medicine, vol. 12, no. 1, pp. 27-33, 2012.
2. C. Bi and W. J. Chng, "MicroRNA: important player in the pathobiology of multiple myeloma," BioMed Research International, vol. 2014, Article ID 521586, 12 pages, 2014.
3. S. Mardente, A. Zicari, F. Consorti et al., "Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary thyroid cancer," Oncology Reports, vol. 24, no. 6, pp. 1455-1461, 2010.
4. A. Hui, C. How, E. Ito, and F.-F. Liu, "Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies," BMC Cancer, vol. 11, article 500, 2011.
5. L. L. Cunha, M. A. Marcello, and L. S. Ward, "The role of the inflammatory microenvironment in thyroid carcinogenesis," Endocrine-Related Cancer, vol. 21, no. 3, pp. R85-R103, 2014.
6. S. Mardente, E. Mari, F. Consorti et al., "HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth andmotility in papillary thyroid cancer cells," Oncology Reports, vol. 28, no. 6, pp. 2285-2289, 2012.
7. M. Korbelik, W. Zhang, and S. Merchant, "Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and highmobility group box-1 release," Cancer Immunology, Immunotherapy, vol. 60, no. 10, pp. 1431-1437, 2011.
8. A. Tsung, S. Tohme, and T. R. Billiar, "High-mobility groupbox in sterile inflammation," Journal of InternalMedicine, vol. 276, no. 5, pp. 425-443, 2014.
9. X. D. Dong, N. Ito, M. T. Lotze et al., "Highmobility group box I (HMGB1) release fromtumor cells after treatment: implications for development of targeted chemoimmunotherapy," Journal of Immunotherapy, vol. 30, no. 6, pp. 596-606, 2007.
10. S. K. Drexler and B. M. Foxwell, "The role of toll-like receptors in chronic inflammation,"The International Journal of Biochemistry and Cell Biology, vol. 42, pp. 506-518, 2010.
11. M. Yu, H. Wang, A. Ding et al., "HMGB1 signals through tolllike receptor (TLR) 4 and TLR2," Shock, vol. 26, no. 2, pp. 174-179, 2006.
12. N. R. Leslie, L. Spinelli, P. Tibarewal et al., "Indirect mechanisms of carcinogenesis via downregulation of PTEN function," Advances in Enzyme Regulation, vol. 50, no. 1, pp. 112-118, 2010.
13. V. G. Antico Arciuch, M. A. Russo, M. Dima et al., "Thyrocytespecific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors," Oncotarget, vol. 2, no. 12, pp. 1109-1126, 2011.
14. C. J. Guigon, L. Zhao, M. C. Willingham, and S.-Y. Cheng, "PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer," Oncogene, vol. 28, no. 4, pp. 509-517, 2009.
15. P. Pallante, R. Visone, C. M. Croce, and A. Fusco, "Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas," Endocrine-Related Cancer, vol. 17, no. 1, pp. 91-104, 2010.
16. S. Yu, Y. Liu, J. Wang et al., "Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma," Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. 2084-2092, 2012.
17. S. Lassalle, V. Hofman, M. Ilie et al., "Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?" Endocrine-Related Cancer, vol. 18, no. 5, pp. 579-594, 2011.
18. Z. Chun-zhi, H. Lei, Z. An-ling et al., "MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN,"BMC Cancer, vol. 10, article 367, 2010.
19. W. A. He, F. Calore, P. Londhe, A. Canella, D. C. Guttridge, and C. M. Croce, "Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 12, pp. 4525-4529, 2014.
20. R. C. Smallridge, L. A. Marlow, and J. A. Copland, "Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies," Endocrine-Related Cancer, vol. 16, no. 1, pp. 17-44, 2009.
21. Z. Liu, P. Hou, M. Ji et al., "Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers," Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 8, pp. 3106-3116, 2008.
22. Y. Arlot-Bonnemains, E. Baldini, B. Martin et al., "Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancerderived cell lines," Endocrine-Related Cancer, vol. 15, no. 2, pp. 559-568, 2008.
23. T. Pilli, K. V. Prasad, S. Jayarama, F. Pacini, and B. S. Prabhakar, "Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer," Thyroid, vol. 19, no. 12, pp. 1333-1342, 2009.
24. M. Yoshida and T. Ueda, "HMGB proteins and transcriptional regulation," Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, vol. 1799, no. 1-2, pp. 114-118, 2010.
25. D. DAngelo, P. Mussnich, R. Rosa, R. Bianco, G. Tortora, and A. Fusco, "High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs," BMC Cancer, vol. 14, article 851, 2014.
26. M. Fabbri, A. Paone, F. Calore et al., "MicroRNAs bind to Tolllike receptors to induce prometastatic inflammatory response," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, pp. 2110-2116, 2012.
27. J. Ma, J. Liu, Z. Wang et al., "NF-kappaB-dependentMicroRNA upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction,"Molecular Cancer, vol. 13, no. 1, article 40, 2014.
28. S. Muniyan, M. A. Ingersoll, S. K. Batra, and M. Lin, "Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor," Biochimica et Biophysica Acta, vol. 1846, no. 1, pp. 88-98, 2014.
29. S. Ivanov, A. M. Dragoi, X. Wang et al., "Anovel role for HMGB1 in TLR9-mediated inflammatory responses to CpGDNA," Blood, vol. 110, no. 6, pp. 1970-1981, 2007.
30. F.-P. Wang, L. Li, J. Li, J.-Y. Wang, L.-Y. Wang, and W. Jiang, "High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK," PLoS ONE, vol. 8, no. 5, Article ID e64373, 2013.